Introduction
============

Sodium selenite (Na~2~SeO~3~) has been proposed as an early treatment of septic shock with discrepant results \[[@B1]-[@B3]\]. Beneficial action is mainly believed through improvement of major antioxidant selenoenzymes, but could on the contrary be related to a therapeutic oxidant action reducing activity of hyperactivated circulating phagocytic cells \[[@B4]\]. It has been suggested that the absence of beneficial effect of high-dose Na~2~SeO~3~continuously administered \[[@B2]\] might be related to toxicity, especially on the lung, of too much selenium (Se) as mentioned in recent parenteral nutrition guidelines in intensive care \[[@B5]\]. On additional clinical and biological data, our purpose was to assess if there was argument for Na~2~SeO~3~toxicity, especially on the lung, under continuous administration of high-dose Na~2~SeO~3~in the SERENITE study.

Methods
=======

In a randomized, double-blind multicenter study performed in 60 septic shock patients \[[@B2]\], the efficacy and tolerance of Na~2~SeO~3~(4 mg Se on day 1 (D1), then 1 mg/day during 9 days or placebo) were evaluated on all components of the SOFA score measured daily, infection rate, and plasma Se, selenoprotein-P (Sel-P), glutathione peroxidase (GPx), lipid peroxidation, cytokines, and procalcitonin measured at D0, D4, D7, D10 and D14.

Results
=======

No deleterious effect of Na~2~SeO~3~especially on the lung was observed for any clinical or biological variables. PaO~2~/FiO~2~was strictly identical between groups (Table [1](#T1){ref-type="table"}). As compared with placebo, mean time occurrences of infections were delayed in the treated group (18 ± 24 days vs. 34 ± 28 days, respectively; *P*\< 0.0001). Plasma Se, Sel-P and GPx concentrations were increased at D4 in the treated group, achieving the high reference value for the plasma Se concentration (Figure [1](#F1){ref-type="fig"}).

###### 

PaO~2~/FiO~2~according to group and time

  -------------------------------------------------------------------------------------
                Baseline\   D2        D3        D4        D7        D10       D14
                (D0)                                                          
  ------------- ----------- --------- --------- --------- --------- --------- ---------
  Na~2~SeO~3~   20 ± 15     23 ± 12   24 ± 10   25 ± 14   26 ± 11   30 ± 13   28 ± 15

  Placebo       22 ± 13     21 ± 11   25 ± 13   26 ± 11   28 ± 14   33 ± 17   36 ± 17

  *P*value      0.60        0.37      0.92      0.81      0.65      0.52      0.13
  -------------------------------------------------------------------------------------

Data presented as mean ± SD (KPa).

![**Plasma Se concentration according to groups and time**. Data presented as mean ± SD (μmol/l). Reference value for plasma Se concentration: 1 ± 0.15 μmol/l. Treated group indicated in blue and nontreated in green.](cc10385-1){#F1}

Conclusion
==========

Continuous administration of high doses of Na~2~SeO~3~(4 mg Se D1) did not induce any deleterious effect in septic shock patients. We did not observe a beneficial effect, contrasting with a comparable study administering Na~2~SeO~3~in bolus, potentially more toxic \[[@B1]\]. In agreement with results obtained on a peritonitis sheep model \[[@B6]\], our data support a therapeutic oxidant action of Na~2~SeO~3~, opening a new field in septic shock treatment based on oxidant selenocompounds.
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